← Back to Screener
Oruka Therapeutics, Inc. Common Stock (ORKA)
Price$60.14
Value ScoreF
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)91.88%
Price vs S&P 500 (4W)-6.88%
VGM Score56.50
Market Capitalization$3.63B
All Metrics
Book Value / Share (Quarterly)$9.70
P/TBV (Annual)2.93x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.82
Price vs S&P 500 (YTD)90.26%
Net Profit Margin (TTM)-26.27%
EPS (TTM)$-2.39
10-Day Avg Trading Volume1.07M
EPS Excl Extra (TTM)$-2.39
EPS (Annual)$-2.31
ROI (Annual)-22.34%
Net Profit Margin (5Y Avg)-9513.58%
Cash / Share (Quarterly)$7.75
ROA (Last FY)-21.58%
EBITD / Share (TTM)$-2.72
ROE (5Y Avg)-24.07%
Operating Margin (TTM)-40.31%
Cash Flow / Share (Annual)$-1.81
P/B Ratio7.45x
P/B Ratio (Quarterly)4.99x
Net Income / Employee (Annual)$-1,550,500
EV / Revenue (TTM)76.35x
Net Interest Coverage (TTM)-69.05x
ROA (TTM)-25.00%
EPS Incl Extra (Annual)$-2.31
Current Ratio (Annual)22.37x
Quick Ratio (Quarterly)23.38x
3-Month Avg Trading Volume1.17M
52-Week Price Return393.36%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)77.40x
Asset Turnover (Annual)0.39x
52-Week High$91.00
Operating Margin (5Y Avg)-9138.63%
EPS Excl Extra (Annual)$-2.31
CapEx CAGR (5Y)59.89%
26-Week Price Return99.80%
Quick Ratio (Annual)21.92x
13-Week Price Return81.31%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)23.76x
Enterprise Value$3.58B
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)14.63%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-26.25%
Cash / Share (Annual)$6.92
3-Month Return Std Dev86.19%
Net Income / Employee (TTM)$-1,709,600
ROE (Last FY)-22.34%
Net Interest Coverage (Annual)-29.41x
EPS Basic Excl Extra (Annual)$-2.31
Receivables Turnover (TTM)10.19x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.39
Receivables Turnover (Annual)10.19x
ROI (TTM)-25.99%
P/S Ratio (TTM)77.40x
Pretax Margin (5Y Avg)-9092.39%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)368.99%
Year-to-Date Return98.42%
5-Day Price Return9.33%
EPS Normalized (Annual)$-2.31
ROA (5Y Avg)-23.01%
Net Profit Margin (Annual)-26.25%
Month-to-Date Return2.75%
EBITD / Share (Annual)$-2.67
Operating Margin (Annual)-40.31%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-24.07%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-2.39
P/TBV (Quarterly)2.00x
P/B Ratio (Annual)3.11x
Pretax Margin (TTM)-26.27%
Book Value / Share (Annual)$9.69
Price vs S&P 500 (13W)73.05%
Beta-0.28x
Revenue / Share (TTM)$0.00
ROE (TTM)-25.99%
52-Week Low$10.77
vGradeF
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.48est. -0.56
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.40
4.40
4.40
4.40
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. Common Stock | F | — | A | $60.14 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibodies for psoriasis and inflammatory diseases. Its lead programs—ORKA-001 and ORKA-002—target distinct inflammatory pathways (IL-23p19 and IL-17A/F) using high-affinity antibodies with extended half-lives to reduce dosing frequency. Both programs address psoriasis, with ORKA-002 also designed for psoriatic arthritis and related conditions.